Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | PGR | P06401 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL6 | P05231 | 1/20 | 0.54 |
| ▸ | GLUL | P15104 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142715 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL3488313 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL7137204 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141852 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL5084683 | 0.99 | HIF1A (0.62) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141360 | 0.98 | HIF1A (0.61) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL1535104 | 0.96 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL29180381 | 0.96 | HIF1A (0.59) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141828 | 0.94 | HIF1A (0.62) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL4450350 | 0.93 | HIF1A (0.61) | HIF1ASMN1; SMN2MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795246-A | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2021-12-14 | — | — | CN | claimed |
| CN-113164043-A | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-110290807-B | Methods of determining CAR-T cell dosing | 朱诺治疗学股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115398231-A | Methods related to toxicity and response associated with cell therapy for treatment of B cell malignancies | 朱诺治疗学股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-113365673-B | High strength porous materials for controlled release | 阿塞斯血管有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113795246-A | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113710256-A | Methods of treatment using adoptive cell therapy | 朱诺治疗学股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113692285-A | Methods of administering and treating B cell malignancies in adoptive cell therapy | 朱诺治疗学股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113365673-A | High strength porous materials for controlled release | 阿塞斯血管有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-111989106-A | Methods of administering and regulating genetically engineered cells | 朱诺治疗学股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| CN-110582287-A | Compositions, articles of manufacture, and methods relating to administration in cell therapy | 朱诺治疗学股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-1889622-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | CXCR3, CFTR, CXCR1 | HIF1A 1897/4885SMN1; SMN2 2899/4885MAPT 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.